Eulerpool Terminal
The edge that pays for itself.
Current GT Biopharma forecasts and price targets in August 2026
Ø Analyst Price Targets
8.16 USD
+2,656.76 %
Median
8.16 USD
+2,656.76 %
Max
8.40 USD
Min
8.08 USD
Last Price
0.30 USD
Buy
6
Hold
1
Sell
0
The average target price for GT Biopharma is 8.16 USD. (+2,656.76 % above the current price)
The median price target of GT Biopharma is 8.16 USD.
Stock analysts from many renowned investment banks are closely examining the GT Biopharma stock. They conclude their professional GT Biopharma stock analyses with a clear recommendation for the GT Biopharma stock. The forecasts and price targets of professional analysts can be a good indicator of how a stock will perform in the next quarter.
| Buy | Hold | Sell | Ø Analyst Price Targets | |
|---|---|---|---|---|
| 2026-02-01 | 6 | 1 | 0 | 8.16 USD |
| 2026-01-01 | 6 | 1 | 0 | 8.16 USD |
| 2025-12-01 | 6 | 1 | 0 | 8.16 USD |
| 2025-12-01 | 6 | 1 | 0 | 8.16 USD |
| 2025-11-01 | 6 | 1 | 0 | 8.16 USD |
| 2025-11-01 | 6 | 1 | 0 | 11.22 USD |
GT Biopharma Stock Forecast 2026: Revenue & Earnings Estimates
Analysts expect the following revenue and earnings for GT Biopharma in the coming fiscal years:
| Fiscal year | Revenue | Net Income | Earnings per share |
|---|---|---|---|
| 2029e | 20.47 B USD | — | — |
| 2030e | 64.80 B USD | — | — |
| 2031e | 97.63 B USD | — | — |